Mechanism of Action (How Tesamorelin Works)
GHRH Receptor Activation: Binds to pituitary GHRH receptors, stimulating GH synthesis and pulsatile release [Falutz 2010].
IGF-1 Elevation: GH stimulates hepatic IGF-1 production, mediating anabolic effects and supporting lean mass accrual [Stanley 2014].
Visceral Fat Reduction: GH/IGF-1 axis activation promotes lipolysis and preferential reduction of visceral adipose tissue [Stanley 2019].
Improved Lipid Metabolism: Decreases triglycerides and improves lipid profiles in research models [Falutz 2011].
Metabolic Remodeling: Enhances protein synthesis, reduces ectopic fat deposition, and supports glucose metabolism [Stanley 2014].
References
Falutz J et al. (2010). Effects of Tesamorelin on Abdominal Fat and IGF-1. NEJM.
https://academic.oup.com/jcem/article-abstract/95/9/4291/2835394Stanley TL et al. (2019). Tesamorelin Reduces Visceral Fat in Obese and HIV-Associated Lipodystrophy Models. Lancet Diabetes Endocrinol.
https://www.natap.org/2019/HIV/PIIS2352301819303315.pdfStanley TL et al. (2014). Changes in Body Composition with Tesamorelin. J Clin Endocrinol Metab.
https://jamanetwork.com/journals/jama/fullarticle/1889139Falutz J et al. (2011). Metabolic Effects of Tesamorelin and GH Modulation. AIDS.
https://peptideinfo.org/tesamorelin




